Search results
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 16 hours agoComprehensive SWOT analysis highlighting Gilead Sciences Inc's strategic positioning in the ...
Earnings call: Aadi Bioscience reports on Q1 2024 and trial updates By Investing.com
Investing.com· 3 hours agoAadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focusing on precision medicines,...
Phanes Therapeutics signs clinical supply agreement with Roche
Clinical Trials Arena via Yahoo Finance· 12 hours agoUS-based biopharmaceutical company Phanes Therapeutics has announced a clinical supply agreement...
Jones Trading cuts Anavex target to $15, maintains buy By Investing.com
Investing.com· 3 hours agoOn Thursday, Jones Trading adjusted its outlook on Anavex Life Sciences (NASDAQ:AVXL), a ...
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between...
NewMediaWire via Yahoo Finance· 7 hours agoFREMONT, CA - (NewMediaWire) - May 09, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a...
Why Is CytomX (CTMX) Stock Down 43% Today?
InvestorPlace· 5 hours agoCytomX Therapeutics (NASDAQ:CTMX) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical...
Unraveling the World of Stable Cell Line Development: A Comprehensive Overview - EconoTimes
EconoTimes· 14 hours agoStable cell line development is a critical process in biopharmaceutical research and production,...
Oncternal Therapeutics: Q1 Earnings Snapshot
Houston Chronicle· 48 minutes agoSAN DIEGO (AP) — Oncternal Therapeutics, Inc. (ONCT) on Thursday reported a loss of $8.4 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of ...
Biodesix Inc (BDSX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
GuruFocus.com via Yahoo Finance· 13 hours agoTotal Revenue: $14.8 million, up 64% year-over-year. Lung Diagnostic Test Revenue: $13.8 million, a 60% increase from the previous year. Biopharmaceutical Services Revenue ...
Regulus Therapeutics (NASDAQ:RGLS) Earns “Buy” Rating from HC Wainwright
ETF DAILY NEWS· 15 hours agoHC Wainwright currently has a $9.00 price target on the biopharmaceutical company’s stock. RGLS has been the topic of a number of other reports. Canaccord Genuity Group decreased ...
